Removal of iron dextran (Cosmofer®) during hemodialysis

Yuqing Chen, Mei Wang
{"title":"Removal of iron dextran (Cosmofer®) during hemodialysis","authors":"Yuqing Chen, Mei Wang","doi":"10.1111/J.1778-428X.2007.00078.X","DOIUrl":null,"url":null,"abstract":"SUMMARY \n \n \nIntravenous iron dextran is widely used in hemodialysis patients receiving erythropoietin (EPO) therapy because of its significant convenience in clinical practice. However, the amount of iron removed by hemodialysis in vivo is unknown. The purpose of this study was to measure the removal of iron dextran in patients undergoing hemodialysis. Six patients were enrolled in this study. All were stable patients treated by hemodialysis for at least 1 month. Both F6 (polysulphone membrane) and GFSplus12 (hemophane membrane) dialyzers were used sequentially in each patient. Each patient received 2 mL of low-molecular-weight iron dextran (Cosmofer® aktieselskab/aksjeselskap and supplied by Zhuhai Schwarz Pharma Company Ltd) intravenously, containing 100 mg of elemental iron, administered during the second hour of dialysis over 30 to 60 minutes. A baseline sample of fresh dialysate was collected before the commencement of dialysis. A control sample of spent dialysate was collected during the first hour of dialysis, before the infusion of low-molecular-weight iron dextran. Then, all spent dialysate after the iron dextran infusion until the end of dialysis was collected. The samples were treated with lanthanum nitrate solution, and the iron content was measured using an atomic-absorptive spectrum method. The iron concentration in the control group was 4.31 ± 2.55 µg/L. After the infusion of iron dextran, the iron concentration in the spent dialysate increased significantly, irrespective of whether an F6 or GFSplus12 dialyzer was used. However, the amount of iron eliminated through the dialyzer was minimal, less than 3% of the infusion dose. There was no significant difference in removal of iron through either the F6 or GFSplus12 dialyzer. These results indicate that the removal of iron dextran by hemodialysis when using either a polysulfphone or hemophane membrane dialyzer is negligible. It is time-efficient and convenient to administer low-molecular-weight iron dextran during hemodialysis.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":"10 1","pages":"22-25"},"PeriodicalIF":0.0000,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2007.00078.X","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion alternatives in transfusion medicine : TATM","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1778-428X.2007.00078.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

SUMMARY Intravenous iron dextran is widely used in hemodialysis patients receiving erythropoietin (EPO) therapy because of its significant convenience in clinical practice. However, the amount of iron removed by hemodialysis in vivo is unknown. The purpose of this study was to measure the removal of iron dextran in patients undergoing hemodialysis. Six patients were enrolled in this study. All were stable patients treated by hemodialysis for at least 1 month. Both F6 (polysulphone membrane) and GFSplus12 (hemophane membrane) dialyzers were used sequentially in each patient. Each patient received 2 mL of low-molecular-weight iron dextran (Cosmofer® aktieselskab/aksjeselskap and supplied by Zhuhai Schwarz Pharma Company Ltd) intravenously, containing 100 mg of elemental iron, administered during the second hour of dialysis over 30 to 60 minutes. A baseline sample of fresh dialysate was collected before the commencement of dialysis. A control sample of spent dialysate was collected during the first hour of dialysis, before the infusion of low-molecular-weight iron dextran. Then, all spent dialysate after the iron dextran infusion until the end of dialysis was collected. The samples were treated with lanthanum nitrate solution, and the iron content was measured using an atomic-absorptive spectrum method. The iron concentration in the control group was 4.31 ± 2.55 µg/L. After the infusion of iron dextran, the iron concentration in the spent dialysate increased significantly, irrespective of whether an F6 or GFSplus12 dialyzer was used. However, the amount of iron eliminated through the dialyzer was minimal, less than 3% of the infusion dose. There was no significant difference in removal of iron through either the F6 or GFSplus12 dialyzer. These results indicate that the removal of iron dextran by hemodialysis when using either a polysulfphone or hemophane membrane dialyzer is negligible. It is time-efficient and convenient to administer low-molecular-weight iron dextran during hemodialysis.
血液透析期间右旋糖酐铁(Cosmofer®)的去除
静脉注射葡聚糖铁因其在临床实践中的显著便利性而被广泛应用于接受促红细胞生成素(EPO)治疗的血液透析患者。然而,血液透析去除体内铁的量是未知的。本研究的目的是测量血液透析患者右旋糖酐铁的去除。6名患者参加了这项研究。所有患者均经血液透析治疗至少1个月,病情稳定。每例患者依次使用F6(聚砜膜)和GFSplus12(血透膜)透析器。每位患者静脉注射2ml低分子铁葡聚糖(Cosmofer®aktieselskab/aksjeselskap,由珠海施瓦兹制药有限公司供应),含100 mg元素铁,在透析后的第二个小时(30 - 60分钟)给予。在透析开始前收集新鲜透析液的基线样本。在透析的第一个小时内,在输注低分子量右旋糖酐铁之前,收集透析液的对照样本。然后收集输注右旋糖酐铁至透析结束后的所有透析液。样品用硝酸镧溶液处理,用原子吸收光谱法测定铁含量。对照组铁浓度为4.31±2.55µg/L。无论使用F6还是GFSplus12透析器,输注右旋糖酐铁后,废透析液中的铁浓度均显著升高。然而,通过透析器消除的铁的量是最小的,不到输液剂量的3%。通过F6或GFSplus12透析器去除铁没有显着差异。这些结果表明,当使用聚砜或血红膜透析器时,血液透析对右旋糖酐铁的去除可以忽略不计。低分子量右旋糖酐铁在血液透析中的应用具有时效性和便捷性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信